At the news
? NEUTRALIMPACT 2/10 425 filed Nov 9, 2026 at 09:08 ET
TriGemX Bio appointed Daniel Lynch as Chairman of its Board, effective immediately and continuing post-merger with TCGX. This is a routine governance update in the ongoing SPAC merger process, with no changes to deal terms, financials, or timeline.
- Daniel Lynch appointed Chairman of TriGemX Bio Board, will remain Chairman after the business combination closes
- Lynch is a veteran biotech executive, former CEO/CFO of ImClone Systems, current Executive Venture Partner at GV
- No changes to deal terms, valuation, PIPE, or expected Q1 2027 closing timeline
- Elismetrep Phase 3 trial results still anticipated in mid-2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access